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ABSTRACT 
EMA Policy 0070 “Phase 1” has been effective since January 2016 and requires CSRs and other 
regulatory documents from central applications to be published in an anonymised format. 
While sponsors are favouring eliminating or minimising risk of re-identification of patients in data made 
public, EMA Policy 0070 requires sponsors to demonstrate that they have prioritised data utility in the 
anonymised CSRs published within the scope of the policy. 
The concept of data utility is not clearly defined in the associated anonymisation guidance and can be 
interpreted from the perspective of different data consumers with different needs and level of skills to 
interpret regulatory clinical documents. 
This paper will elaborate on the concept of data utility as outlined in EMA Policy 0070 and explore how 
different stakeholders (researchers, patients, health professionals, etc.) may use this wealth of 
information that has recently been made available in the context of central applications. 
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DEFINITIONS 
Abbreviation /Term Definition 
AE Adverse Event 
CCI Company Confidential Information 
ClinicalTrials.gov US Clinical Trials Database 
CSR Clinical Study Report 
DIA Drug Information Association 
EMA European Medical Agency 
EU European Union 
EudraCT European Clinical Trials Database 
FDA Food and Drug Administration 
HTA Health Technology Assessment 
IPD Individual Patient Data 
LPLV Last Patient Last Visit 
PII Personal Identifying Information 
SAE Serious Adverse Event 
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INTRODUCTION 
Clinical Study Reports (CSRs) represent a wealth of information related to design, conduct and analysis of trials, in 
addition to more comprehensive trial results compared to publicly available databases such as journal manuscripts of 
clinical trials and clinical trial registries. Doshi 2013 [1] refers to CSRs as an “hitherto mostly hidden and untapped 
source of detailed and exhaustive data on each trial.” and addresses the concept of “compression factor” defined as 
the ratio of CSR page length compared to the page length of the same trial as published in scientific journals which 
ranged from 1 up to 8,805 based on the review of 78 CSRs.  
Previous work has highlighted the impact of selective outcome reporting [2, 3], in that the data and results published 
within a journal manuscript may be incomplete or misleading, and the biases that originate from this selective 
reporting. Increasingly, researchers undertaking secondary analyses of clinical trial data such as systematic reviews 
and meta-analyses are seeking access to previously confidential regulatory documents as a means of assessing and 
reducing the impact of any selective reporting bias, generating more complete and reliable information and 
investigating clinical questions which could not have previously been considered using published data sources alone 
[4 - 15].  
In the context of Policy 0070 “Phase 1”, where anonymised CSRs are made public, a myriad of data recipient groups 
could be considered together with various objectives for reviewing and using the information within these anonymised 
CSRs. The EMA external guidance [16] does not clearly identify these different data consumer groups and their 
intentions or objectives. However, from an anonymisation perspective, such considerations could help to define better 
anonymisation approaches, in addition to ensuring that adequate data utility for the purposes of the data recipients is 
retained. 
The concept of data utility appears to be an important criterion for the anonymised CSRs to meet the objectives of 
EMA Policy 0070 “Phase 1”. Reference is made in several sections of EMA Policy 0070 CSR anonymisation external 
guidance and in its Anonymisation Report template that the data controller must demonstrate that data utility has 
been considered and optimised. 
Despite the apparent importance of this criteria, the EMA external guidance does not define or quantify the utility of 
anonymised CSRs and "Data Utility" is also absent within section "3. Definitions" of the EMA external guidance. A 
definition from the Organization for Economic Co-operation and Development (OECD) is: “A summary term 
describing the value of a given data release as an analytical resource. This comprises the data’s analytical 
completeness and its analytical validity. Disclosure control methods usually have an adverse effect on data utility. 
Ideally, the goal of any disclosure control regime should be to maximise data utility whilst minimising disclosure risk. 
In practice disclosure control decisions are a trade-off between utility and disclosure risk.” [17]. 
For any public data release, there are intended data consumers and other data consumers (not primarily intended) 
that may also benefit from the data. The objective of this paper is to itemise who and how anonymised CSR data 
could be used by intended data consumers by reviewing possible data consumer groups, their purposes and the 
potential data utility associated with their purpose. 
The research presented in this paper was conducted between February and October 2017. 
It is outside the scope of this paper to discuss the redaction of Company Confidential Information (CCI) and its 
implication on data utility and not intended data consumers such as hackers or bodies following non-scientific 
purpose. 
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INSIGHTS FROM POLICY 0043 REQUESTS 
EMA Policy on access to documents (related to medicinal products for human and veterinary use) also known as 
“Policy 0043” has been effective since 2010 and enables individuals and parties to request access to documents. The 
scope of Policy 0043 is not limited to regulatory documents such as CSRs but can provide some insights on how 
much data has been requested by different bodies. Requesting documents through Policy 0043 is a controlled 
process and requesters must identify themselves as part of the request process that also includes a possible appeal 
in case of a rejection. The purpose of the request is however not required to be documented as part of the request. 
Table 1 below summarises the number of requests and number of pages released per affiliation and was made public 
in 2016 [0]. A breakdown of the information within Table 1 relating to the type of documents requested was not 
available. 
Table 1 – Policy 0043 documents requests per affiliation 
 
We, Jean-Marc Ferran (JMF) and Sarah Nevitt (SN), had an opportunity to discuss the data presented in Table 1 with 
EMA representatives and they confirmed that requesters under “Legal” and “Consultant” are mostly professionals 
from or contracted by the pharmaceutical industry. The category “Pharmaceutical industry” both includes companies 
from the innovative and generic industry. No distinction was made. 
Grouping together the first 7 rows from “Not-for-profit organisation” to “Academia/Research institute”, the number of 
requests received represent 18.6% while “Legal”, “Pharmaceutical Industry” and “Consultant% represent 76% of 
requests. However, when comparing the number of pages released, the two groups are approximately equivalent 
with 52.3% and 45.6% respectively. This shift is mainly explained by the large number of pages in regulatory 
documents that are often requested and released to Academia/Research institutes (31.59%) while other subgroups 
are more likely to request other documents (e.g. meeting minutes) that represent few pages. It is indeed possible to 
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request a set of documents (e.g. all CSRs used in a submission) within one single request. It must also be noted that 
requests from “Patients or Consumers” represent 6.68% of all requests and 9.55% of pages released.  
It may not be possible to directly extrapolate these figures from Policy 0043 (a controlled process covering all types of 
documents) to Policy 0070 (public access to regulatory documents part of a central application), but the affiliations 
described within Table 1 provide an indication of who the data consumers of Policy 0070 may be. While the 
Pharmaceutical Industry themselves and Academia / Research Institutes are likely to be the main data consumer of 
Policy 0070 documents, it cannot be excluded that “highly literate” patients or patient representatives may also 
benefit from such data being made public (almost 10% of all pages released in 2016). 
NOTE: We (JMF and SN) were provided with the data in Table 1 and further interpretations from discussions with 
EMA representatives towards the end of the present research that was conducted and is summarised in this paper. 
Further research on Policy 0043 requests, particularly relating to the types of documents requested by each data 
consumer group could help understanding better similar concepts in Policy 0070. 
DATA CONSUMER SCENARIOS 
Our first consideration during this research focused on determining data consumer groups that may use Anonymised 
CSRs and their purpose, noting that documents are complex and lengthy and require expertise to read, understand 
and process. 
Conceptually, we considered two scenarios. The first scenario is built on the assumption that only highly skilled 
individuals or groups may invest time and efforts in working with such documents and that other potential data 
consumers would benefit from the findings of this highly skilled group and indirectly consume anonymised CSRs. The 
second scenario assumes that various data consumer groups would have the skills, educate themselves or contract 
other skilled professionals to consume these documents for various purposes. 
The following subsections describe in more detail the subgroups and mechanism in terms of how knowledge can be 
derived and who are the primary and secondary data consumers on anonymised CSRs made public. 
SCENARIO 1: SIMPLIFIED “SKILL-BASED” SCENARIO 
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Figure 1 - Simplified "Skill-based" Scenario Flow 
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Figure 1 represents the first scenario where only highly skilled individuals and bodies would use anonymised CSRs. 
Researchers would conduct novel or secondary analyses such as systematic reviews and meta-analysis to derive 
knowledge that would be published and disseminated to Clinical Practitioners and Patient Associations who will then 
translate the findings to patients. 
Other Pharmaceuticals would be able to consume the documents relating to similar compounds in order to inform 
their clinical trials and clinical programs. In the particular case of drug repurposing (i.e. the application of existing 
compounds to new indications), access to CSRs from previous studies is key. Also, within the scenario of the 
rejection or withdrawal of a central application of a competitor, access to CSRs could provide valuable lessons for 
further submissions or even lead to re-investment of resources within an alternative, perhaps more promising, clinical 
program. Similarly, other Pharmaceuticals and Regulators may also benefit from published novel research conducted 
by researchers, who in turn, may benefit from advances in clinical trial design and clinical programs conducted within 
the Pharmaceutical Industry. 
SCENARIO 2: VERSATILE USE ACROSS DATA CONSUMERS 
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Figure 2 – Versatile use across Data Consumers Scenario Flow 
 
In a second scenario illustrated in Figure 2, patients would form three group: “Expert” Patients, “Clinical Trial” Patients 
and “Non-Expert” Patients. Policy 0043 data shows that “Patients or Consumers” have requested nearly 10% of all 
pages released in 2016 and it is assumed here that “Expert” Patients who are highly literate will be using Anonymised 
CSRs to better understand their disease and available treatments. In this scenario, Clinical Practitioners and Patient 
Associations would also use such reports to also advise on clinical trial participation, clinical trial designs and use in 
HTA process. On the right-hand side, the three different types of patients (that may overlap, e.g. a patient is 
participating in a clinical trial and is highly literate about the diseases) would benefit directly or indirectly from all the 
knowledge derived by other bodies. 
The paper will explore how plausible these two scenarios are through review of potential uses of the anonymised 
CSRs across data consumer groups. 
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RESEARCHERS AND RESEARCH GROUPS 
From previous work which has made use of regulatory documents for secondary analyses [4 -15], it is expected that 
the research community, such as research groups comprised of academic and clinical researchers, and medical 
statisticians, will be the primary users of the anonymised CSRs. 
A short summary [18] of advantages and disadvantages in using CSRs versus published articles for Cochrane review 
highlights the extra information and opportunities as well as challenges working with CSRs for academics.  
Jefferson [19] refers to a survey conducted among Cochrane authors (31,901 authors – not all active) between June 
and September 2016 about their experience (if any) using regulatory data (defined as CSRs and other regulatory 
documents). Initial results of the survey showed that among 156 respondents that only 10% used or requested 
regulatory data, 5% considered using regulatory data and 85% have not considered using regulatory data. Among the 
10% of respondents who have used or requested regulatory data, 80% believes that regulatory data should be used 
on Cochrane reviews while this number falls to 38% and 32% for the ones who considered regulatory data and the 
ones who have not consider regulatory data. Source of data requests that were reported were pharma (11) and 
regulators (7). CSRs were used by 8 authors to supplement published trial data in meta-analyses. But 67% of 
respondents who accessed and included data in their reviews mentioned barriers when using data: limited data 
sharing/restricted access and expertise and skills required. Other interesting data shows that 32% of respondents 
had no understanding of the regulatory process and documents developed and only 12% of authors knew where to 
access regulatory data. Further results of this survey will soon be published [20]. 
These results demonstrate that using regulatory data is rather new for the academic community but researchers who 
are requesting or using regulatory documents to complete Cochrane Reviews consider access to these documents 
important and values for their analyses. The field is merely a “new born” and more examples of how regulatory data 
for secondary analyses can be used should emerge in the coming years.  
Results of the survey also suggested that the availability of further guidance on how to interpret and use regulatory 
data in secondary analyses would help to promote the use of CSRs in Cochrane Reviews [20,21]. An “Interim 
guidance on the inclusion of Clinical Study Reports and other regulatory documents in Cochrane Reviews” is being 
developed. 
Researchers and research groups may wish to use the anonymised CSRs for a range of different research purposes 
and using variety of techniques and methods. Some of the research purposes are outlined in this section; in general 
terms, these purposes fall into two categories, data and method comparison and novel analyses, although some 
research purposes may overlap these categories. 
DATA AND METHOD COMPARISON: DETAILED ASSESSMENT OF STUDY METHODS AND EVALUATION OF RISK OF BIAS 
A potential purpose of gaining access to complete information regarding trial design and conduct may be used by 
researchers to inform the design of future trials. 
A more common reason for using CSRs, as discussed in the introduction of this paper, to access to detailed trial 
methodology and comprehensive results within anonymised CSRs allows for assessment of bias in the trial design 
and any selective outcome reporting bias in journal manuscripts [2, 3]. For example, by comparing the information in 
CSRs and other regulatory documents to published trial reports for 20 trials of Gabapentin, Vedula et al [15] identified 
selective outcome reporting for trials of off-label use of gabapentin which threatens the validity of evidence for the 
effectiveness of off-label interventions. Eyding et al [4] also discovered that published data overestimated the benefit 
of reboxetine versus placebo by up to 115% and reboxetine versus SSRIs by up to 23%, and also underestimated 
harm compared to the information presented in CSRs and other regulatory documents. 
Similarly, by comparing publications of Orlistat trials to their corresponding CSRs, both Scroll et al [9] and Hodkinson 
et al [10] identified that journal publications provided insufficient information on harms outcomes of clinical trials and 
in some cases, inconsistent numbers of adverse events were reported across different documents relating to the 
same trial. Further examples of research using CSRs and other regulatory documents can be found in Appendix 1. 
DATA AND METHOD COMPARISON / NOVEL ANALYSIS: USE OF NARRATIVES, INDIVIDUAL PARTICIPANT LISTINGS & 
EVALUATION OF HARM 
Summary of AEs are required to be made public in ClinicalTrials.gov and EudraCT. However, a number of examples 
of under-reporting or misleading reporting of harms in publically available reports of clinical trials compared to the 
more detailed harms information available in CSRs have been published (see Appendix 1).  
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These publications highlight that review of individual narratives and participant listings (Note that participant listings 
are out-of-scope of Policy 0070 “Phase 1”) for Serious Adverse Events and other Adverse of Events of interest would 
help researchers understanding further the safety profile of the drug beyond review of summary statistics of 
dictionary-coded events and verify safety data in CSRs. We explore here 2 publications from Emma Maund and 
colleagues [13-14]. 
Maund 2014 [13] is a methodological paper relating to different conclusions that can be drawn from reading summary 
tables of AEs which are usually dictionary coded, compared to reading verbatim descriptions in the narratives. Their 
illustrative example shows that coded events and narratives suggest different numbers of events related to suicide 
and the authors conclude that in this case the narratives are more informative and coded events in summary tables 
may be misleading and may not fully capture the true nature of the event. The paper states that “narratives of 
adverse events can provide additional information, including original investigator reported adverse event terms, which 
can enable a more accurate estimate of harms”. “Using the patient’s trial identification number we were able to 
reconcile data reported in the patient listings with those in the narrative. Secondly, using data (treatment assignment, 
coded term, and timing of event) from the patient listings and narratives, we were able to reconcile data from these 
two formats with the data in summary tables.” 
Maund 2016 [14] is a clinical paper (a meta-analysis) relating to the benefit and harms of a drug for a particular 
indication. The authors are interested in some specific harms, related to suicide and violence, due to FDA concerns 
about the association between this drug and these SAEs. The authors use data from CSRs (summary tables and 
narratives) to perform their analyses and the discussion compares the results of this analysis to a Cochrane review of 
the same topic conducted only with data available in the public domain (i.e. from trial publications). The two analyses 
come to overall the same conclusions (i.e. that clinical benefits of the drug in question do not outweigh the potential 
harms) but the two analyses consider different outcomes sets and show slightly different results for common 
outcomes. Notably, the analysis of CSR data has allowed more detailed considerations of specific adverse events 
which would not have been possible without access to CSRs and narratives. For example, in Maund 2016 [14], “one 
patient had a “nervous breakdown,” which was coded as mental disorder, and another patient reported “feeling 
drugged,” which was coded as somnolence. In addition, 5 patients, all receiving duloxetine, experienced a total of 8 
events that were mentioned only in the narrative text.” 
The ability to follow a patient through narratives, conserve sequence and distance between events, findings and 
interventions and access the investigator reported terms seem essential for the work described above. Availability of 
demographics and medical history among others could also support more detailed analyses. 
NOVEL ANALYSIS: USE OF UNPUBLISHED SUMMARY DATA FOR SYSTEMATIC REVIEWS AND META-ANALYSES 
Researchers performing systematic reviews and meta-analyses, such as Cochrane Reviews, can take one of two 
approaches; either using summary (aggregate) data only or performing a re-analysis of individual participant data 
(IPD). Using IPD has many advantages for meta-analysis and allows more complex research questions to be 
considered. Researchers can request access to IPD from pharmaceutical trials via data sharing platforms such as 
CSDR [22] and YODA [23]. However, an IPD approach to meta-analysis is very resource and time consuming and 
may not be necessary if published and unpublished aggregate data can answer the clinical question [24]. 
Therefore, to increase the precision and reliability of systematic review and meta-analysis results, researchers may 
wish to use unpublished summary (aggregated) data from one or more CSRs within systematic reviews and meta-
analyses. In 2014, Jefferson et al [15] reported on the first Cochrane review to be based on all relevant full clinical 
study reports of a drug, augmented by regulatory comments. 
Summary statistics and details of the statistical analyses of primary and secondary efficacy endpoints are required to 
be made public in ClinicalTrials.gov and EudraCT 30 days after submission approval and 6 (paediatric trial) to 12 
(adult-only trial) months after Last Patient Last Visit (LPLV) for any trial conducted in Europe respectively and would 
be available in such registries outside an EMA central application. However, previous work has shown that such 
publically available information may not be sufficient [5], particularly for the objectives of an original systematic review 
or meta-analysis. Additionally, the format that the summary results are provided in may not readily allow the inclusion 
of the information within meta-analysis (for example, where a measure of precision of the treatment effect is not 
published). 
A CSR would typically contain more details about the choice of statistical method, interpretation of results and the full 
set of endpoints, results and statistics at all time points measured and therefore may provide a useful supplementary 
source of data for systematic reviews and meta-analysis. For example, a review of 101 CSRs conducted by Wieseler 
et al [5] shows that CSRs provided complete information on 78% to 100% of benefit outcomes (compared to 20% to 
53% from publically available sources), CSRs also provided considerably more information on harms and on patient-
relevant outcomes such as outcomes describing morbidity, mortality, and health-related quality of life (HRQoL). This 
research group emphasise that it is essential that sufficient information is available to patients and clinicians on 
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benefits, harms and patient-relevant outcomes when new drugs become available [6,7]. 
We describe two examples of projects that Sarah Nevitt (née Nolan) has been involved in to demonstrate the 
rationale and reasons for conducting an IPD analysis compared to using unpublished summary data (e.g. from CSRs) 
in secondary analysis. Both projects were conducted as Cochrane Reviews, but the level of analysis involved was 
very different. 
The first project is an IPD meta-analysis of Epilepsy trials [26]. The primary outcome of this analysis is time-to-
treatment withdrawal which is a complex outcome and often reported differently across studies, so to perform a meta-
analysis, the definition of this outcome had to be standardised. Often, free text or ‘verbatim’ reasons for an individual 
withdrawing from treatment were required within the IPD, to ensure the correct classification of reasons for withdrawal 
within the re-analysis of the IPD. Furthermore, an objective of this analysis was to examine differences in treatment 
response across different patient subgroups (such as different epilepsy types and different ages). Such information 
will never be available to the required level in the public domain, so IPD and statistical expertise to perform the 
appropriate analysis to address this question is required. 
The gain in knowledge provided by IPD in this analysis allowed for two drugs which were considered to be 
approximately equivalent in terms of their effectiveness as anti-epileptics, to be separated in a number of respects. 
For example, one of the drugs was shown to have an advantage over the other in terms of effectiveness (i.e. time to 
treatment withdrawal), while the opposite effect was shown when considering only the efficacy of the drugs in 
controlling seizures (i.e. time to 12-month remission of seizures). Such findings allow a more personalised approach 
medical decision making to specific subgroups of patients depending on their priorities and requirements of an anti-
epileptic medication. 
The second project is a Cochrane review of Mannitol (a new drug) for Cystic Fibrosis [25]. Regulatory objectives 
within clinical trials often focus on efficacy of new compounds (e.g. lung function within Cystic Fibrosis) as 
demonstration of efficacy over placebo or a standard treatment is usually required for a new product to be licenced. 
However, the focus of the Cochrane Collaboration is often around patient important outcomes such as Quality of Life 
or Burden of treatment which are often more meaningful indicators of clinical status and improvement to patients.  
While the main published sources of new regulatory trials (journal articles, Clinical trials.gov etc.) focus on efficacy 
outcomes such as lung function, very little information was reported regarding on Quality of Life or other patient 
reported outcomes. Therefore, the manufacturer of Mannitol (Pharmaxis), were contacted by SN and the Cochrane 
Review team and the manufacturer provided unpublished summary data (aggregate data), allowing for all of the 
patient reported outcomes relevant to the Cochrane Review to be reported in a great level of detail. To clarify, it was 
not CSRs specifically that were made available by the manufacturers, but the level of information required for the 
Cochrane review would have certainly been available in CSR.  
The unpublished data was then synthesised within the Cochrane review using ‘standard’ meta-analysis methodology 
which would not necessarily require the support of a statistician. SN became involved in the project due to her 
experience of requesting unpublished regulatory data, but if this information had been available in the public domain, 
a statistician’s expertise would not have been needed for this project. 
EXAMPLES OF USE OF CSRS BY ACADEMIC RESEARCHERS 
In a presentation given at DIA 2017 by Tom Jefferson in Glasgow [19], the following journal publications were listed 
as examples of academic work using CSRs in secondary research: 
• Eyding et al 2010 [4]  
• Le Noury et al 2015 [8]   
• Schroll  et al 2016 [9] 
• Hodkinson et al 2016 [10]  
• Jefferson et al 2014 [11]  
• Maund et al 2014 [13]  
• Vedula et al 2009 [15]  
A summary of the regulatory data sources, methods and conclusions of these manuscripts is provided in Appendix 1. 
These manuscripts are based on CSRs that were gathered before the implementation of EMA Policy 0070. Most of 
these manuscripts tend to demonstrate publication bias, reporting inconsistencies and/or provide new knowledge 
about drug efficiency and benefit/harm ratio using meta-analyses.  
We are providing this summary from a methodological perspective on use of regulatory data in academic research. It 
must be noted that this is a ‘selective sample’ of academic work which has mostly shown changes in conclusions, 
particularly regarding harms of drugs, when re-analysing clinical trial data using CSRs and the re-analysis 
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approaches taken by some of the academic research groups have been challenged by the pharmaceutical 
companies in questions and response articles published on journal websites, linked to the academic work in question. 
This sample should not be considered completely reflective of academic objectives for accessing regulatory data or a 
comprehensive list of all research using CSRs (which is likely much wider as indicated by the number of requests 
from Table 1). The selective nature of the sample summarised here must be taken into account when interpreting the 
findings in the context of all published research making use of unpublished regulatory information.  
We (JMF and SN) attempted to make contact with the authors of the publications listed above to further explore the 
use of CSRs in the projects and the potential impact that EMA Policy 0070 may have on the data utility of 
anonymised CSRs in secondary research. Full details of the correspondence with authors is provided in Appendix 2. 
In summary, all of the authors stated that their analyses would not have been possible without access to CSRs. None 
of the authors raised any specific concerns about anonymised or redacted CSRs (in line with EMA Policy 0070). In 
fact, one research team had used CSRs publically available from a sponsor website which were redacted and this 
redaction did not impact upon the analysis from the author’s recollection. Furthermore, none of the authors stated that 
their team had any difficulties in interpreting the information from the CSRs; the only problems related to ‘illegible’ text 
or the format of the documents which prevented electronic searching. 
All of the authors stated that some or all of their analyses or research would not have been possible if narratives 
and/or appendices (with participant listings) were removed from anonymised CSRs under EMA Policy 0070. One 
author stated that: “Anonymised CSRs are ok, but the current EMA policy redacts important information about when 
the adverse events appeared as well as what they were. Newer CSRs does not have individual adverse event listings 
and the EMA are not even in possession of them.” Another author with knowledge of Policy 0070 stated that: “I have 
actually looked at data that are released under the EMAs new policy 0070, and they do provide fully redacted CSRs. 
So yes, I would say you could use these provided the drug is centrally licenced. But redactions may permit what data 
can be used, and they may not be of use for creating IPD datasets without the subject IDs and other patient-level 
information.” 
It should be emphasised that these observations are anecdotal and rhetorical as these projects were based on CSRs 
that were obtained before the implementation of EMA Policy 0070. However, these observations and the rationales of 
the type of analyses being conducted using CSRs do raise some potential issues relating to data utility of documents 
anonymised under EMA Policy 0070 “Phase 1”. The full extent and any impact of such issues will not become 
apparent until sufficient research projects are conducted and published using anonymised CSRs prepared in line with 
EMA Policy 0070. 
COMPETITORS / OTHER PHARMACEUTICALS 
As outlined conceptually in Figure 1, other pharmaceuticals (including competitors) would be able to consume the 
documents relating to similar compounds in order to inform their clinical trials and clinical programs. Competitors can 
gain knowledge about similar drugs and design better their studies. 
 
Gaining insight into similar compounds’ clinical trial results may also help competitors to stop “bound-to-fail” clinical 
programs earlier and reinvest resources on promising drugs. In the scenario of the rejection or withdrawal of a central 
application of a competitor, access to CSRs could provide valuable lessons for further similar submissions. The case 
of drug repurposing also require access to all possible data from previous studies in other indications. 
Bonini et al. 2014 [30] refers to “optimising future study designs with regard to population selection and sample size, 
choice of outcomes, definition of clinically relevant differences for various end points, or identification of biomarkers 
for better disease phenotyping”. Policy 0070 “Phase 1” also provide access to data and information on more 
endpoints, subgroup, full set of analyses on same endpoints in comparison with EudraCT and ClinicalTrials.GOV. 
European citizens can already request CSRs through EMA Policy 0043 but this is a lengthier process (up to several 
months).  
CLINICAL PRACTITIONERS 
As outlined conceptually in Figure 2, clinicians such as general practitioners, nurse specialists, consultants etc. may 
wish to review details within CSRs not published in the public domain and understand better the safety and efficacy 
profile of the drugs they prescribe and to better inform their patients on drug choices and clinical trial participation. 
At the time of the draft EMA Policy 0070 being on review, several of the comments came from practising clinical 
practitioners but this was only a small number of the people who could have actually commented. 
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The comments at the time were all supportive of the policy and referred to recent examples in the media where initial 
data conclusion, and drug approvals, were overturned when additional data was further analysed. 
In recent follow up with a sample (n=5) of these practitioners they reflected on their reasons for submitting comments 
and that they were statements of support. Furthermore, they confirmed that they have no directly interest in producing 
research and meta-analysis to investigate data reports but rather want reassurances that researchers are able to 
access reports and data to continue to produce additional analyses. 
PATIENTS / PATIENTS’ ASSOCIATIONS 
Lay Summaries are probably more accessible to Patients but it cannot be excluded that “Highly Literate and Expert” 
patients (typically in chronic diseases) would be able to make use of anonymised CSRs and have had the opportunity 
so far to request relevant CSRs through Policy 0043. As part of this research, we have not been able to get further 
insight on how Patients would use anonymised CSRs. 
A review of the comments sent from patients’ and consumers’ associations on the initial draft version of EMA Policy 
0070 in 2013 (also covering sharing of IPD, known now as “Part II” and not finalised yet) [27] shows that:  
• The initiative is received very positively  
• There are concerns around current Informed Consent forms that patients signed 
• There are concerns around possibility of wrong secondary analyses 
• They do not believe there are CCI in clinical trials data 
• Patients privacy is of utmost importance 
A number of patients’ & consumers’ organisations have also been contacted to provide input: 
• BEUC (http://www.beuc.eu/ ): Participated in an interview 
• ECPC (http://www.ecpc.org/ ): No answer 
• EURORDIS (http://www.eurordis.org/ ): Participated in an interview. 
• Genetic Alliance (http://www.geneticalliance.org/ ): Participated in an interview. 
• EPF (http://www.eu-patient.eu/ ): Answered it was too early to reflect on how patients would be using these 
reports but would like to contribute in the future. 
Organisation “Understanding Patient Data” (https://understandingpatientdata.org.uk/) was also contacted and 
communicated that there was no plan for the moment to develop guidelines for patients to help them understand and 
use CSRs. 
BEUC (The European Consumer Organisation) is an umbrella organisation for EU consumers association. We spoke 
with a representative from the Health& Food department who underline the importance of making such data available 
in the public domain to ensure transparency of the information flow from a consumer’s perspective and increase trust 
in regulators. 
EURODIS and Genetic Alliance represent patients with rare diseases. These associations also contribute to clinical 
research and public affairs. 
According to a representative of EURODIS, CSRs provide much more detailed data compared to public registries. 
However: 
• Data from Phase I/II are essential to recommend rare disease patients which clinical studies to join in the 
lack of a variety of available treatments. This would require phase I/II clinical studies CSRs to be available 
early while Policy 0070 “Phase 1” makes the submissions of anonymised CSRs at the time of the drug 
submission and would not address this need.  
• Placebo data can be used to understand better the disease from this controlled and carefully monitored 
population. 
• CSRs may help to inform better Academic Strategic Clinical Trials aiming at learning when to start and how 
to use better the available treatments. 
• Indirect comparison of drugs could be supported 
• CSRs could be used to support discussions between Community Advisory Board. (Patients representative 
interacting with sponsor on methods and logistics, etc.) and sponsors on Clinical Trials throughout the entire 
compound Life Cycle. 
• In the case of drug repurposing (from e.g. a frequent to a rare disease area), having access to all previous 
data is of the utmost importance and would speed up the process. 
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• In general, rare diseases require other policies than Policy 0070 to address earlier and faster access to data 
including access to IPD. 
• It was noted that patients with rare diseases considering the often genetic roots of the disease are 
concerned over privacy as data breach may also affect their relatives. 
According to a representative of Genetic Alliance: 
• CSR data can be used to build stronger cases in HTA work and provide stronger arguments towards 
investment and research.  
• Patient Association giving evidence based on full range of treatments to a level of professionalism that 
matches what is produced by other stakeholders would be a significant step forward and help patients 
having a higher impact. 
• Privacy may be a secondary concern for certain people who have rare disease in contrast with developing 
adequate treatments for their diseases but this opinion may only be UK specific. 
DISCUSSION 
SUMMARY OF FINDINGS AND IMPLICATIONS 
CSRs have previously been considered as an ‘untapped’ source of detailed information relating to design, conduct 
and analysis of clinical trials. The value of the information within CSRs is becoming increasingly recognised within the 
academic research community, particularly within the Cochrane Collaboration and an “Interim guidance on the 
inclusion of Clinical Study Reports and other regulatory documents in Cochrane Reviews” is being developed. 
It is already compulsory that aggregated data from primary and secondary outcomes of clinical trials is public in the 
EudraCT database within 6 to 12 months from LPLV for most studies conducted in Europe. While such data may be 
suitable and sufficient to support some secondary analyses such as meta-analysis, anonymised CSRs provides 
complete information and data on study and statistical methods, interpretation of results and the full set of endpoints’ 
results and statistics and would certainly enable verification of numerical results and assessments and conduct meta-
analyses using data from all endpoints. 
EMA Policy 0070 “Phase 1”, where anonymised CSRs are made public, is likely to further facilitate the secondary use 
of the information within CSRs. However, little consideration has been given to the data utility of the anonymised 
information within CSRs under Policy 0070. The objective of this paper was to identify data recipient groups with a 
range of purposes and to investigate the data utility of anonymised CSRs associated with various purposes. 
Based on the number of requests made under EMA Policy 0043, we anticipate that researchers or research groups 
and the Pharmaceutical Industry are likely to be the primary recipients of anonymised CSRs under EMA Policy 0070 
as described in Scenario 1: Simplified “Skill-based” Scenario. The research examples we discuss within this paper 
indicate that the objectives and scopes of secondary analysis and novel research that have been conducted using 
CSR data are vast. Authors of such research have communicated with us their concerns over the type of research 
that could be conducted in the future if information such as participant listings or narratives are redacted or removed 
completely under EMA Policy 0070. 
It should be noted that not all data consumers would benefit from complex data available in a CSR and it could be 
justified to focus on most relevant data consumers in terms of data utility if not all needs can be met. In reality, it is 
likely that clinical practitioners, Patient Associations and patients themselves will indirectly gain knowledge from 
anonymised CSRs via the disseminated published findings of new research rather than these consumers using 
regulatory documents directly. However, it cannot be excluded that as in Scenario 2: Versatile Use across Data 
Consumers, “highly literate” patients or patient representatives would wish to access anonymised CSRs released 
under Policy 0070; almost 10% of all pages released in 2016 under EMA Policy 0043 were requested by patients or 
consumers. 
Keeping similar conclusions and primary and secondary analyses in the Anonymised CSRs similar to the ones 
available in the Scientific CSR is of utmost importance. Handling of narratives seems to be the most difficult aspect of 
the policy from a technical standpoint and various levels of anonymisation would define further different levels of data 
utility together with the handling of in-text listings. There are examples in the literature on how narratives are used to 
verify safety conclusions (see Appendix 1 for examples). 
Certain free-text fields such as e.g. Adverse Events Reported Terms or Reason for Withdrawal may be instrumental 
for certain secondary analysis to e.g. verify dictionary coding and conduct re-analysis [13] or map reason for 
withdrawal consistently across studies in the case of meta-analysis [26]. Further, preserving Subject IDs and Dates in 
an anonymised format would help using the narratives in particular in order to follow a patient throughout the Adverse 
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Events and use sequences and distances to understand. Free-text variables are often redacted in both IPD and 
documents when a dictionary-coded variable is available and generally better suited for analysis. The PhUSE De-
Identification standard [31] recommends as primarily rule in the case of pro-active release of data to follow such 
rational and a secondary rule to “Review and redact PII” in such free-text variables. It is therefore advised to 
researchers to make it clear in their requests to pharmaceutical companies whether certain free-text variables must 
be retain even though a dictionary-coded variable is available in the given data domain. In the case of public release 
of documents, should such free-text variables be retained, processing to ensure no PII remains prior to publication is 
essential. 
Patient Associations raised the concern of the risk of wrong secondary analysis in their initial comments to Policy 
0070 received in 2013 [27]. In the case of research request sent directly to pharmaceutical companies and for IPD 
requests made via ClinicalStudyDataRequest.com (or a single sponsor platform), a clause is present within Data 
Sharing Agreements specifying that in the case of detection of a new safety signal, the researcher must inform the 
regulatory authorities and pharmaceutical companies immediately. In the case of Policy 0070, there are no such 
expectations and any new findings (also related to new safety signals) are discussed through public academic 
debates.  
Further understanding of the safety profile of the drugs and verification of how conclusions of clinical studies are 
derived is certainly an added value for many stakeholders and data consumer groups. However, several academic 
publications that were reviewed in the paper and described in Appendix 1 have had their findings challenged by 
concerned pharmaceutical companies through comments on journals web-sites. Discussion of academic findings and 
interpretations should always be encouraged but there is a risk that ‘rapid-response’ additional analyses as a 
challenge to published research may confuse readers and secondary data consumers such as clinical practitioners, 
patients and Patient Associations who cannot interpret which of the many published results are the correct ones. 
Bonini et al. 2014 [30] also mentions that “access to clinical data imposes a high ethical standard on anyone using 
those data, lest inappropriate reanalyses breed unjustified concern about the efficacy or safety of marketed drugs.” 
We (SN and JMF) suggest that communication between academic research groups and pharmaceutical companies 
regarding interpretations of regulatory data and results from their different perspectives during the research projects 
before publications within journals may provide the most informative novel results and in turn, provide the most 
benefit to readers and data consumers. 
LIMITATIONS 
The work presented within this paper is on a small number of interviews and e-mail communications conducted with 
Researchers, Patient Associations, Doctor Associations rather than a systematic survey across a significant 
population of data consumers. Therefore the findings presented within this paper represent only tendencies to 
explore further. Particularly, certain data consumers, their purposes and any associated data utility such as “Other 
Pharmaceuticals”, “Generics” or “Regulators” should be investigated further.  
It must be emphasised that the examples of academic research using CSRs summarised within this paper are a 
selective sample and do not necessarily represent all research objectives which would make use of anonymised 
CSRs under EMA Policy 0070. Further, most observations provided to us by data consumers and our interpretations 
are rhetorical, rather than based on direct experience of anonymised CSRs and the validity of these observations 
may not become clear for some time. 
FUTURE CONSIDERATIONS 
“Phase 2” of EMA policy 0070 on sharing of IPD should provide the next level of data utility that is required to conduct 
robust secondary analyses. A number of sponsors already provide access to anonymised IPD based on research 
request for studies based on different criteria (e.g. EFPIA commitment [29]). “Phase 2” of the policy that is planned in 
the future should in principle systemise the access to anonymised IPD for studies part of a central application in EU 
regardless of the outcome of the application. The needs of the research community often include access to full 
patient listings which is out of scope of Policy 0070 “Phase 1” and may be addressed in “Phase 2” of the policy.  
In addition more guidance on using regulatory documents is required to researchers, patients and anyone from the 
general public in order to make the best use of such publicly available data. 
In conclusion, EMA guidance refers to various levels of anonymisation but based on level of risk of re-identification of 
patients rather than different levels of data utility and this paper can hopefully help to consider the anonymisation 
problem from both perspectives. This research field is “merely a new born” and more experience from use and 
findings based on Policy 0070 data should be reviewed in the future. 
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APPENDICES 
APPENDIX 1: EXAMPLES OF ACADEMIC WORK USING CSRS IN SECONDARY RESEARCH  
Drug under 
consideration 
and references 
Regulatory data 
Source(s) 
Methods Manuscript Conclusion* 
Reboxetine  
Eyding et al [4] 
13 CSRs and other 
regulatory documents 
from published and 
unpublished trials 
provided by Pfizer 
• Data and method 
comparison   
(CSRs and protocols 
compared to trial 
manuscripts, trial registries 
and regulatory authority 
websites). 
• Data extraction  
• Systematic review and 
meta-analysis 
• AE counts 
• Published data overestimated the benefit of reboxetine versus placebo by up to 115% 
and reboxetine versus SSRIs by up to 23%, and also underestimated harm. 
• Reboxetine is, overall, an ineffective and potentially harmful antidepressant. Published 
evidence is affected by publication bias, underlining the urgent need for mandatory 
publication of trial data. 
Paroxetine and 
imipramine  
Le Noury et al 
[8] 
Individual participant 
data, CSR and 
Appendices available 
on GSK website and 
additional appendices 
provided by GSK for 
one trial (Study 329) 
• Data and method 
comparison   
(IPD, CSR and original 
analysis compared). 
• Re-analysis 
• AE counts 
 
• Neither paroxetine nor high dose imipramine showed efficacy for major depression in 
adolescents, and there was an increase in harms with both drugs.  
• Access to primary data from trials has important implications for both clinical practice 
and research, including that published conclusions about efficacy and safety should 
not be read as authoritative.  
• The reanalysis of Study 329 illustrates the necessity of making primary trial data and 
protocols available to increase the rigour of the evidence base. 
Orlistat  
Schroll et al [9] 
7 CSRs provided by 
Roche 
• Data and method 
comparison   
(CSRs compared to 
protocols and trial 
manuscripts). 
• AE counts 
 
• For one trial, an additional 1,318 adverse events were identified that were not listed or 
mentioned in the CSR itself but could be identified through manually counting 
individual adverse events reported in an appendix. The majority of patients had 
multiple episodes of the same adverse event that were only counted once, though this 
was not described in the CSRs. 
• In the orlistat trials, we identified important disparities in the reporting of adverse 
events between protocols, clinical study reports, and published papers. Reports of 
these trials seemed to have systematically understated adverse events. Based on 
these findings, systematic reviews of drugs might be improved by including protocols 
and CSRs in addition to published articles. 
Orlistat  
Hodkinson et al 
[10] 
5 CSRs provided by 
Roche 
• Data and method 
comparison   
(CSRs compared to trial 
manuscripts). 
• AE counts 
 
• Journal publications provided insufficient information on harms outcomes of the Orlistat 
trials and did not specify that a subset of harms data were being presented.  
• CSRs often present more complete data on harms, including serious adverse events 
• CSRs could support a more complete, accurate, and reliable investigation, and 
researchers undertaking evidence synthesis of harm outcomes should not rely only on 
incomplete published data that are presented in the journal publications. 
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Oseltamvir  
Jefferson et al 
[11] 
83 CSRs obtained from 
EMA and Roche, of 
which 23 were used in 
the systematic review 
and meta-analysis  
• Data and method 
comparison   
(CSRs compared to trial 
manuscript). 
• Data extraction  
• Systematic review and 
meta-analysis 
• AE counts 
• This is a report of the first Cochrane review to be based on all relevant full clinical 
study reports of a drug, augmented by regulatory comments. 
• The trade-off between benefits and harms should be borne in mind when making 
decisions to use oseltamivir for treatment, prophylaxis, or stockpiling. 
Duloxetine 
Maund et al [12 
-14] 
9 CSRs and protocols 
as appendices obtained 
from the EMA. 
• Data and method 
comparison   
(CSRs compared to 
protocols, trial manuscripts 
and clinicaltrials.gov 
entries). 
• Data extraction  
• Systematic review and 
meta-analysis 
• AE counts 
• CSRs contained extensive data on harms that were unavailable in journal articles and 
trial registry reports. There were inconsistencies between protocol and CSRs. 
• The listings of adverse events for individual patients and narratives of adverse events 
within CSRs can provide additional information, including original investigator reported 
adverse event terms, which can enable a more accurate estimate of harms. 
• Following re-analysis using data from CSRs, the apparent harms of Duloxetine 
outweigh the benefits 
Gabapentin  
Vedula et al [15] 
20 CSRs (and other 
regulatory documents 
such as protocols) 
provided by Pfizer and 
Parke-Davis 
• Data and method 
comparison   
(CSRs and other regulatory 
documents compared to 
published trial 
manuscripts). 
 
• For 8 of the 12 trials reported as trial manuscripts, the primary outcome differed in the 
published trial compared to the CSRs / protocol 
• Other sources of disagreement between published trials and regulatory documents 
included introduction of a new primary outcome, failure to distinguish between primary 
and secondary outcomes, relegation of primary outcomes to secondary outcomes and 
failure to report one or more protocol-defined primary outcomes. 
• This selective reporting of off-label use of gabapentin which threatening the validity of 
evidence for the effectiveness of off-label interventions 
*: NOTE: Some of the findings of these research papers have been challenged by the concerned pharmaceutical companies and responses to manuscripts have been 
published on the journal website. 
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APPENDIX 2: CORRESPONDENCE WITH AUTHORS OF MANUSCRIPTS USING CSRS FOR RESEARCH 
Conversation with Dr Jon Jureidini, 18 August 2017. 
Dr Jureidini was involved in the project relating to the manuscript: 
Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in 
treatment of major depression in adolescence. BMJ 2015;351:h4320. doi: 10.1136/bmj.h4320 
Dr Jureidini spoke to Sarah Nevitt regarding this project on 18 August 2017. This appendix summarises the key 
findings of this work with comments from Dr Jureidini (conversations summarised by SN, comments are not direct 
quotes from Dr Jureidini). 
This was the first study published using data from CSDR. The authors also used CSRs which were available on the 
GSK website (including appendices) that had been redacted to some extent. The initial reporting of Study 329 has 
been considered controversial, hence this research team wished to perform a re-analysis with the original data and 
regulatory documents of Study 329. The original analysis found the drugs to show efficacy with limited harms (only 
significant adverse events reported). The re-analysis shows that neither drug actually shows any efficacy, and there 
was an increase in harms from both drugs. 
Comment from Dr Juredini (on the rationale for the work): Everyone is interested in efficacy of the drugs and p 
values. This is what the main papers always concentrate on and the harms are always a secondary consideration. 
We should be more interested in the harms of the data, these are never reported enough and it can be hard to get 
people interested in harms. To get a full picture of potential harms, you need to look a lot deeper into the data and the 
CSRs – this will never be fully captured in a trial publication. 
There were clear issues with the initial publication of Study 329 – not fraudulent, the authors were very honest, 
almost too honest as it revealed that the efficacy they described was at odds with the data. This became even more 
evident looking at the CSRs. 
The use of CSRs in this project was for the harms data. The authors recoded some of the narrative descriptions of 
adverse events. Due to unclear descriptions within the publically available appendices from the GSK website, the 
authors requested an extra unpublished extra appendix of the study CRFs. This was provided via the CSDR remote 
data access system. 
Comment from Juredini: The system was so cumbersome and difficult to access that due to the time involved of 
recoding and comparing adverse events, we only completed this task for around a third of AEs; the AEs we 
considered to be the most important. We were criticised for this by reviewers of the BMJ article but as we had no 
funding and limited resources for this analysis but didn’t have a lot of choice. 
The redaction of information from narratives and appendices didn’t really cause any issues as far as I can recall. The 
problem was that some of the text was illegible – maybe due to the age of the document which wasn’t helped by the 
remote data access system which prevented zooming in, using software to improve quality etc. 
We had no problem with the content or interpreting the documents etc. The problems were with the quality of the 
documents and trying to use them in the remote system. 
This analysis would have been impossible without access to the appendices and it would be ‘travesty’ if the 
implication of EMA Policy 0070 means that appendices are completely redacted or no longer shared. 
Correspondence with Dr Beate Wieseler, 20 August 2017 
Questions were sent to Dr Wiesler by Sarah Nevitt to further explore the use of CSRs in the project relating to the 
manuscript 
Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review 
and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. 
BMJ 2010;341:c4737. doi: 10.1136/bmj.c4737 
Dr Wieseler provided the following additional references reporting on the experiences of the research group using 
CSRs 
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Wieseler B, Wolfram N, McGauran N, et al. Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: 
Comparison of Unpublished Clinical Study Reports with Publicly Available Data. PLOS Medicine 
2013;10(10):e1001526. doi: 10.1371/journal.pmed.1001526 
Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of 
clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ. 2012 Jan 
3;344:d8141. 
Köhler M, Haag S, Biester K, Brockhaus AC, McGauran N, Grouven U, Kölsch H, Seay U, Hörn H, Moritz G, Staeck 
K. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus 
regulatory reports, journal publications, and registry reports. BMJ. 2015 Feb 26;350:h796. 
Dr Wiesler also provided the following responses to the questions by e-mail and is happy for the responses to be 
reported in this paper:  
1. Could you explain the rationale for using CSRs for your research (rather than published trial reports, IPD 
etc.)? 
We are interested in the full evidence base of the interventions under assessment in our Health Technology 
Assessment reports to be able to provide unbiased assessments for decision making in the German health care 
system. By using regulatory documents like CTD clinical overviews and clinical summaries and specifically CSRs we 
want to overcome publication and outcome reporting bias.  
Specifically we need full information on trial methods including the study protocol with any amendments and the 
statistical analysis plan (SAP) to be able to understand the study planning or any changes in the conduct of the study 
or the analyses. Among other things we use this information to choose relevant endpoints/analyses and assess the 
risk of bias on a study or endpoint level. Journal publications and registry reports do not provide the level of detail we 
need. E.g. journal publications do not provide full inclusion/exclusion criteria or full specification of endpoints or 
statistical analyses (including information on handling of missing or specification of statistical methodology like 
models used in the analyses.)  
Furthermore, we need full numerical summary data on all endpoints (including information on which 
endpoints/analyses were pre-specified or defined post-hoc) to be able choose the endpoints/analyses relevant to our 
assessment and to conduct meta-analyses. Often numerical information in journal publications is too limited for meta-
analysis. We are also interested in subgroup or sensitivity analyses which also might not be presented in documents 
other than the CSR.  
2. Were any specific outcomes reported within the CSRs for interest to you? 
We are specifically interested in patient-relevant outcomes (i.e. outcomes describing how a patient feels, functions or 
survives). Often these endpoints are secondary endpoints which are not fully published in journals. Our research has 
described and quantified to which extent we could add endpoints from CSRs as compared to other sources (BMJ 
2012;344:d8141, PLoS Med 10(10): e1001526; BMJ 2015;350:h796) 
3. Which sections of the CSRs did you use for your research (e.g. summary tables, narratives, appendices, 
participant listings, others sections etc.)  
We use the full CSR including end-of-text tables and appendices for our work. 
4. If you used the narratives, can you explain exactly what you used them for? For example, did you wish to 
extract participant level information to create a dataset 
We rarely use narratives because the information we use in most cases is available also in other data presentations 
(e.g. listings or summary tables of SAEs). However, if these other data presentations are missing, we might extract 
information from narratives. 
5. Did you have any difficulties in extracting or interpreting information from the CSRs? 
We do not have difficulties in extracting or interpreting information from well written CSRs.  
6. Were there any key findings of your research specifically relating to the use of CSRs? 
The CSRs of reboxetine allowed to assess all evidence available in a situation where only a biased set of studies was 
published in journals (please see BMJ 2010;341:c4737). We have been able to extract substantially more 
methodological and endpoint information for our assessments from CSRs than from other sources (please see 
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references given under Question 2). Futhermore, often we were only able to understand a study included in our 
assessment fully by using the CSR including the protocol and SAP (please see Z Evid Fortbild Qual Gesundhwes. 
2017 Feb;120:3-8 for a description of the example of our assessment of liraglutide). 
7. Would you have been able to complete this research without access to CSRs? 
Without CSRs we would have missed important information. 
8. Would you have been able to complete this research if narratives and/or appendices (with participant 
listings) had been removed from the CSRs? 
We definitely do need appendices including protocols and amendments and the SAP. If we need participant listings 
depends on the open questions that arise from the assessment (see e.g. the assessment of liraglutide in which we 
needed the information of when hypoglycemic events occurred in individual patients).  
9. Would you have been able to complete this research if you had been provided with anonymised CSRs (in 
line with EMA policy 0070)? 
In rare cases I can forsee that we need to follow study participants through several listings. This would only be 
possible if there is some kind of ID (not necessarily the original ID from the study).  
Correspondence with Dr Jeppe Schroll, 31 August 2017 
Questions were sent to Dr Schroll by Sarah Nevitt to further explore the use of CSRs in the project relating to the 
manuscript 
Schroll JB, Bero L, Gotzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 
2013;346:f2231. doi: 10.1136/bmj.f2231 
Dr Schroll provided the following responses by e-mail and is happy for the responses to be reported in this paper:  
1. Could you explain the rationale for using CSRs for your research (rather than published trial reports, IPD 
etc.)? 
The purpose of our paper was to compare published with unpublished data. 
2. Were any specific outcomes reported within the CSRs for interest to you? 
We covered reported adverse event and methods on how to handle adverse events. Lots of outcomes were reported 
that were not available in the publications 
3. Which sections of the CSRs did you use for your research (e.g. summary tables, narratives, appendices, 
participant listings, others sections etc.)  
We used summary tables, appendices and narratives and participant listings. For our CSR individual patient listings 
of adverse events were available. 
4. If you used the narratives, can you explain exactly what you used them for? For example, did you wish to 
extract participant level information to create a dataset 
We explored the reason for discontinuation and found divergence from the listing of withdrawals. In the narratives the 
sponsors’ causality assessment was available. 
5. Did you have any difficulties in extracting or interpreting information from the CSRs? 
It was a great difficult that the documents were not in a “text readable” format. Which made electronic searching 
impossible. The pages had more than one page number and there was – in out material – no overall table of 
contents. Only for the specific sections. 
6. Were there any key findings of your research specifically relating to the use of CSRs? 
We found that a lot of data is left out of the publications and that important limitations and assumptions were not 
described.  
7. Would you have been able to complete this research without access to CSRs? 
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No 
8. Would you have been able to complete this research if narratives and/or appendices (with participant 
listings) had been removed from the CSRs? 
No 
9. Would you have been able to complete this research if you had been provided with anonymised CSRs (in 
line with EMA policy 0070) 
Anonymised CSRs are ok, but the current EMA policy redacts important information about when the adverse events 
appeared as well as what they were. Newer CSRs does not have individual adverse event listings and the EMA are 
not even in possession of them. 
Correspondence with Professor Catrin Tudur Smith and Dr Alex Hodkinson, September 2017  
Questions were sent to Professor Tudur Smith (CTS) and Dr Hodkinson (AH) by Sarah Nevitt to further explore the 
use of CSRs in the project relating to the manuscript 
Hodkinson A, Gamble C, Smith CT. Reporting of harms outcomes: a comparison of journal publications with 
unpublished clinical study reports of orlistat trials. Trials 2016;17(1):1-11. doi: 10.1186/s13063-016-1327-z 
 
Professor Tudur Smith (CTS) and Dr Hodkinson (AH) provided the following responses by e-mail and is happy for the 
responses to be reported in this paper:  
1. Could you explain the rationale for using CSRs for your research (rather than published trial reports, IPD 
etc.)? 
CTS: As a methodological exercise to compare the information available in CSR s versus information available in 
published journal articles 
AH: Really this was just a methodological piece of work displaying the value of CSRs when there evidence for 
underreporting of harms in published literature. 
2. Were any specific outcomes reported within the CSRs for interest to you? 
CTS: Adverse events only 
AH: All harm outcomes (AEs and SAEs) but also the timing of events, grading and safety narratives if reported 
3. Which sections of the CSRs did you use for your research (e.g. summary tables, narratives, appendices, 
participant listings, others sections etc.)  
CTS: We didn’t receive narratives but this may have provided additional information. The main source of information 
we used were the IPD listings of adverse events and tables 
AH: Roche I believe have changed the format of their CSRs since this piece of work, but data were primarily obtained 
from the following sections:  
• Module I (core report which follows the ICH E3 format): sections 2.6 (safety parameters), 2.9.4 (Safety 
analysis), 3.4 (safety results). 
• Modules II: glossary of original and MedDRA preferred terms for AEs 
• Module V: section 5, Safety analysis plan 
 
4. If you used the narratives, can you explain exactly what you used them for? For example, did you wish to 
extract participant level information to create a dataset 
AH: No we didn’t use the safety narratives, as they were rarely reported. If they were reported consistently we may 
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have been able to create an IPD dataset. 
5. Did you have any difficulties in extracting or interpreting information from the CSRs? 
CTS: Large documents that are difficult to navigate at first but they were well structured and so quite straightforward 
to locate the information 
AH: Not really, other than Roche had removed a number of pages in one of the CSRs and redacted quite a lot of 
information throughout. We did contact them about this, apparently there was some confidential information on these 
pages. I wasn’t convinced. 
6. Were there any key findings of your research specifically relating to the use of CSRs? 
CTS: We found additional information and additional detail available in the CSRs but also additional time required to 
extract the information 
AH: Obviously there were high numbers of AE and particularly SAEs that were not reported in the publication (see 
bar graphs in paper), and 5 statistically significant harm outcomes were detected using the CSRs. 
7. Would you have been able to complete this research without access to CSRs? 
CTS: No 
AH: Due to the underreporting of harms data in publications probably not. CSRs are far more detailed than 
publications, and I would recommend they are used where possible for synthesis of harms. 
8. Would you have been able to complete this research if narratives and/or appendices (with participant 
listings) had been removed from the CSRs? 
AH: N/A as we didn’t use the safety narratives, and the participant listing of AEs in Module IV of the report were 
removed. 
9. Would you have been able to complete this research if you had been provided with anonymised CSRs (in 
line with EMA policy 0070) 
CTS: Possibly 
AH: I have actually looked at data that are released under the EMAs new policy 70, and they do provide fully 
redacted CSRs. So yes, I would say you could use these provided the drug is centrally licenced. But redactions may 
permit what data can be used, and they may not be of use for creating IPD datasets without the subject IDs and other 
patient-level info. 
